C******6
发帖数: 22 | 1 积累了二十多年，2013 年爆发。股票长了258%。Kynamro 产品销售前景不看好，但对
将来制药厂行业方向有重大影响。350 人，市值46亿美元，平均13M/person。
Isis Pharmaceuticals , Inc. (NASDAQ:ISIS)‘ Kynamro probably isn’t going to
reach blockbuster status anytime soon, if ever. The drug treats a rare
disease that causes patients to have dangerously high cholesterol levels.
And it appears Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)‘ Juxtapid,
which was approved in late 2012, will take most of the market.
But the approval makes the top three for 2013 because Kynamro is the first
second-generation RNA antisense drug to be approved. Rather than acting on
the protein level to inhibit targets, RNA antisense drugs act upstream of
protein synthesis, promoting RNA degradation, which lowers the expression of
the protein. | r*****o
发帖数: 82 | 2 看好Isis
to
★ 发自iPhone App: ChineseWeb 8.2.2
【在 C******6 的大作中提到】
: 积累了二十多年，2013 年爆发。股票长了258%。Kynamro 产品销售前景不看好，但对
: 将来制药厂行业方向有重大影响。350 人，市值46亿美元，平均13M/person。
: Isis Pharmaceuticals , Inc. (NASDAQ:ISIS)‘ Kynamro probably isn’t going to
: reach blockbuster status anytime soon, if ever. The drug treats a rare
: disease that causes patients to have dangerously high cholesterol levels.
: And it appears Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)‘ Juxtapid,
: which was approved in late 2012, will take most of the market.
: But the approval makes the top three for 2013 because Kynamro is the first
: second-generation RNA antisense drug to be approved. Rather than acting on
: the protein level to inhibit targets, RNA antisense drugs act upstream of
|
|
